| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/04/2006 | US7022525 Process of making a compound by forming a polymer from a template drug |
| 04/04/2006 | US7022521 Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents |
| 04/04/2006 | US7022509 Gas vesicles of cells and methods of harvesting, isolating and modifying same |
| 04/04/2006 | US7022483 Methods for identifying and isolating antigen-specific T cells |
| 04/04/2006 | US7022364 Sugar-free hard coatings prepared from liquid mixtures of erythritol and sorbitol |
| 04/04/2006 | US7022349 Antihistamine composition |
| 04/04/2006 | US7022345 Oral solid pharmaceutical formulations with pH-dependent multiphasic release |
| 04/04/2006 | US7022344 Process for producing solid dosage forms |
| 04/04/2006 | US7022343 In situ polymerization on heart; biodegradation |
| 04/04/2006 | US7022339 Antidiabetic preparation for oral administration |
| 04/04/2006 | US7022338 A pressed tablet was prepared in low pressure, no heat generated, with the help by adding oligosaccharides, polysaccharides, and adding slime-forming agent for targeting gastro-intestinal tract; Streptococcus, Lactobacillus, Bifidobacterium; stable viability; biodrugs |
| 04/04/2006 | US7022336 Methods for attaching proteins to lipidic microparticles with high efficiency |
| 04/04/2006 | US7022330 Dissolving epothilone analog such as ixabepilone in a mixture of tertiary-butanol in water to form a solution; drying solution; lyophilizing; drying in vacuum; packaging lyophilized product in a first vial and packaging second vial with nonionic surfactant |
| 04/04/2006 | US7022315 Administering a thiol-based chemoprotectant agent intra-arterially for therapy and prophylaxis of side effects of cytotoxic cancer therapy for tumors located in the brain, head or neck |
| 04/04/2006 | US7022314 Anti-plaque emulsions and products containing same |
| 04/04/2006 | US7022313 Hydrogel particle formulation |
| 04/04/2006 | US7022312 Condensation aerosol as doage forms, is produced by heating a thin layer containing of dolasetron, granisetron or metoclopramide to form vapor, condense into an aerosol; fast producing peak plasma concentrations |
| 04/04/2006 | CA2265532C Process for producing solid dosage forms by extrusion |
| 04/04/2006 | CA2257305C Marking rapidly disintegrating dosage forms |
| 04/04/2006 | CA2181072C Estradiol penetration enhancers |
| 03/30/2006 | WO2006033948A2 Sustained local anesthetic composition containing preferably a sugar ester such as saib |
| 03/30/2006 | WO2006033433A1 Wound remedy |
| 03/30/2006 | WO2006033296A1 Novel block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient |
| 03/30/2006 | WO2006032762A2 Pharmaceutical composition comprising a solid dispersion with a polymer matrix containing a continuous polydextrose phase and a continuous phase of a polymer other than polydextrose |
| 03/30/2006 | WO2006032675A1 Aqueous pharmaceutical preparation comprising roflumilast |
| 03/30/2006 | WO2006032624A1 Pharmaceutical composition for transdermal administration |
| 03/30/2006 | WO2006032461A1 Stable dosing form of phenylalanine derivatives |
| 03/30/2006 | WO2006032144A1 Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using fucans from various echinoderm sources |
| 03/30/2006 | WO2006032143A1 Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans |
| 03/30/2006 | WO2006017374A3 Nutritional supplement composition and method |
| 03/30/2006 | WO2006000920A3 Dimensional analysis of saccharide conjugates with gpc & sec-mals |
| 03/30/2006 | WO2005123137A3 Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride |
| 03/30/2006 | WO2005108463A3 Branched polyethylen glycol derivates comprising an acetal or ketal branching point |
| 03/30/2006 | WO2005103710A3 Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 1 (crhr1) |
| 03/30/2006 | WO2005102275A3 Galantamine salts, method of producing it and nasal composition thereof |
| 03/30/2006 | WO2005102274A3 Method of stabilizing disordered cefovecin sodium salt |
| 03/30/2006 | WO2005095460A3 Bi-specific antibodies for targeting cells involved in allergic-type reactions, compositions and uses thereof |
| 03/30/2006 | WO2005077333A3 Gel-based delivery of recombinant adeno-associated virus vectors |
| 03/30/2006 | WO2005074901A3 New effector conjugates, process for their production and their pharmaceutical use |
| 03/30/2006 | WO2005070471A3 Articles comprising magnetic material and bioactive agents |
| 03/30/2006 | WO2005058367A3 Pegylated small molecules |
| 03/30/2006 | WO2005048993A3 Minimization of drug oxidation in drug irradiated excipients formulations |
| 03/30/2006 | WO2005046573A3 Pro104 antibody compositions and methods of use |
| 03/30/2006 | WO2005013896A3 Programmed immune responses using a vaccination node |
| 03/30/2006 | WO2004070012A3 Cell-killing molecules and methods of use thereof |
| 03/30/2006 | WO2003062369A3 Expansion of renewable stem cell populations |
| 03/30/2006 | US20060069238 Synthetic glyco-lipo-peptides as vaccines |
| 03/30/2006 | US20060069237 Sterically hindered poly (ethylene glycol) alkanoic acids and derivatives thereof |
| 03/30/2006 | US20060069230 Biodegradable polyketal polymers and methods for their formation and use |
| 03/30/2006 | US20060069168 Vascular embolization material |
| 03/30/2006 | US20060069162 Transparent eye drops containing latanoprost |
| 03/30/2006 | US20060069154 Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs |
| 03/30/2006 | US20060069114 Liquid pharmaceutical formulations of palonosetron |
| 03/30/2006 | US20060069113 Analgesic compositions containing buprenorphine |
| 03/30/2006 | US20060069033 Use of poly-amminopyrrolecarboxamides alone or in combination with a cyclodextrin in the prophylaxis and treatment of animal parasitosis |
| 03/30/2006 | US20060069028 A carbamate or urea containing comopound is useful to treat angiogeneisis; methionine aminopeptidase 2 (MetAP-2) coupled to a peptide prevents the metabolic degradation of the angiogenesis inhibitor compound |
| 03/30/2006 | US20060068034 nose spray lipophilic medicament comprising tetrahydrocannabinol and cannabidiol, and cannabis plant extract as the drug substance; free from self emulsifying agent and/or a fluorinated propellant; administered by a pump action spray |
| 03/30/2006 | US20060068016 Paticulate product comprising pantethine |
| 03/30/2006 | US20060068006 Edible holographic products, particularly pharmaceuticals and methods and apparatus for producing same |
| 03/30/2006 | US20060067988 Pharmaceutical formulations designed to supplement the diet of anorexic patients |
| 03/30/2006 | US20060067987 Salt-free fermented soybean paste-like food material, obtained by hydrolyzing soybean and a sub-material with a koji mold |
| 03/30/2006 | US20060067986 Mixture of milk, protein such as casein and enzyme inhibiting peptide |
| 03/30/2006 | US20060067985 Hypoallergenic composition |
| 03/30/2006 | US20060067966 Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| 03/30/2006 | US20060067946 Method of treatment using ligand-immunogen conjugates |
| 03/30/2006 | US20060067944 Stable immunogenic product comprising antigenic heterocomplexes |
| 03/30/2006 | US20060067929 Administering a modified Clostridial toxin with a proteolytic domain; a translocation domain and an orphanin targeting moiety; the HC domain is removed or modified to reduce the targeting of the modified Clostridial toxin to the neuromuscular junction. |
| 03/30/2006 | US20060067928 Contacting a linear polysaccharide with a disaccharide repeat unit of a uronic acid [ alpha -L-iduronic acid (I) or beta -D-glucuronic acid] linked 1, 4 to alpha -D-hexosamine with a modified heparinase III in vitro |
| 03/30/2006 | US20060067910 Polyethylene glycol-polyglutamic acid block copolymer conjugates with e.g. 7-ethyl-10-hydroxycamptothecin or topotecan for sustained release; water solubility, anticancer agents |
| 03/30/2006 | US20060067909 Peptide-modified polyurethane compositions and associated methods |
| 03/30/2006 | US20060067898 10 weight % terbinafine hydrochloride, 0.5 % dodecyl 2-(N,N-dimethylamino)propionate hydrochloride and 0.75 % benzyl alcohol to enhance penetration; 0.5 % polyvinylpyrrolidone, and the remainder ethanol; duel delivery through nail and skin increases topical bioavailability; onychomycosis |
| 03/30/2006 | US20060067892 Topical nanoparticulate spironolactone formulation |
| 03/30/2006 | US20060067885 ablating a targeted non-malignant B cell, comprising administering to a human subject having an immune disease an unconjugated monoclonal antibody (LL2 antibody) which binds to a marker that is specific for a B cell |
| 03/30/2006 | US20060067881 Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products |
| 03/30/2006 | US20060064943 Capsule filling machine |
| 03/30/2006 | DE102004035606A1 Carrier für Arzneimittel zur Gewinnung der oralen Bioverfügbarkeit Carrier for drugs used for obtaining the oral bioavailability |
| 03/30/2006 | CA2623471A1 Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans |
| 03/30/2006 | CA2581423A1 Polipeptide compounds for inhibiting angiogenesis and tumor growth |
| 03/30/2006 | CA2581287A1 Sustained local anesthetic composition containing bupivacaine and saib |
| 03/30/2006 | CA2581143A1 Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof |
| 03/30/2006 | CA2580722A1 Sustained release pharmaceutical composition |
| 03/30/2006 | CA2580639A1 Stable dosing form of phenylalanine derivatives |
| 03/30/2006 | CA2580397A1 Aqueous pharmaceutical preparation comprising roflumilast and an alkoxylated fat |
| 03/30/2006 | CA2580141A1 Cysteine engineered antibodies and conjugates |
| 03/30/2006 | CA2579905A1 Cytotoxicity mediation of cells evidencing surface expression of mcsp |
| 03/30/2006 | CA2579673A1 Pharmaceutical composition comprising a solid dispersion with a polymer matrix containing a continuous polydextrose phase and a continuous phase of a polymer other than polydextrose |
| 03/29/2006 | EP1640799A1 Laser projector |
| 03/29/2006 | EP1640452A1 OLIGO DOUBLE-STRANDED RNA INHIBITING THE EXPRESSION OF Bcl-2 AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
| 03/29/2006 | EP1640022A1 Menthol-containing preparation |
| 03/29/2006 | EP1640019A1 Sustained-release fine granular preparation of human growth hormone and process for producing the same |
| 03/29/2006 | EP1640006A1 Sustained drug-relase particles and process for producing the same |
| 03/29/2006 | EP1639999A1 Nonaqueous pressure-sensitive adhesive for medicinal tape preparation for percutaneous absorption, medicinal tape preparation for percutaneous absorption, and process for producing the same |
| 03/29/2006 | EP1639997A1 Matrix for sustained, invariant and independant release of active compounds |
| 03/29/2006 | EP1639996A1 Matrix for sustained, invariant and independant release of active compounds |
| 03/29/2006 | EP1639991A2 Skin and tissue care and/or treatment composition |
| 03/29/2006 | EP1639092A2 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| 03/29/2006 | EP1639029A2 Biodegradable poly(beta-amino esters) and uses thereof |
| 03/29/2006 | EP1639000A2 Compositions and methods for the diagnosis and treatment of tumor |
| 03/29/2006 | EP1638609A1 Method for the preparation of molecular complexes |
| 03/29/2006 | EP1638608A1 ENHANCEMENT OF DEVELOPMENT OF OVIPAROUS SPECIES BY i IN OVO /i FEEDING OF ENTERIC MODULATORS |